An Empirical Biomarker-based Calculator for Autosomal Recessive Polycystic Kidney Disease The Nieto-Narayan Formula
Jake A Nieto, Michael A Yamin, Itzhak D. Goldberg, Prakash Narayan
Abstract
Autosomal polycystic kidney disease (ARPKD) is associated with progressive enlargement of the kidneys fuelled by the formation and expansion of fluid-filled cysts. The disease is congenital and children that do not succumb to it during the neonatal period will, by age 10 years, more often than not, require nephrectomy+renal replacement therapy for management of both pain and renal insufficiency. Since increasing cystic index (CI; percent of kidney occupied by cysts) drives both renal expansion and organ dysfunction, management of these patients, including decisions such as elective nephrectomy and prioritization on the transplant waitlist, could clearly benefit from serial determination of CI. So also, clinical trials in ARPKD evaluating the efficacy of novel drug candidates could benefit from serial determination of CI. Although ultrasound is currently the imaging modality of choice for diagnosis of ARPKD, its utilization for assessing disease progression is highly limited. Magnetic resonance imaging or computed tomography, although more reliable for determination of CI, are expensive, time-consuming and somewhat impractical in the pediatric population. Using a well-established mammalian model of ARPKD, we undertook a big data-like analysis of minimally- or non-invasive serum and urine biomarkers of renal injury/dysfunction to derive a family of equations for estimating CI. We then applied a signal averaging protocol to distill these equations to a single empirical formula for calculation of CI. Such a formula will eventually find use in identifying and monitoring patients at high risk for progressing to end-stage renal disease and aid in the conduct of clinical trials.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=181 SRC=\"FIGDIR/small/064139_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (31K):\norg.highwire.dtl.DTLVardef@6fb814org.highwire.dtl.DTLVardef@9e597borg.highwire.dtl.DTLVardef@4d81aorg.highwire.dtl.DTLVardef@7c642_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Apelin inhibits cyst growth and improves kidney function in mice with polycystic kidney disease
Duuamene Nyimanu, Anubhav Chakraborty, … A. Ershova Yu.·bioRxiv·Mar 30, 2026
- Cystin is required for maintaining fibrocystin (FPC) levels and safeguarding proteome integrity in mouse renal epithelial cells A mechanistic connection between the kidney defects in cpk mice and human ARPKDRunning title: Cystin deficiency results in FPC degradation
- c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease
Abigail O. Smith, Julie A. Jonassen, … Gregory J. Pazour·PLoS GeneticsPeer-reviewed·Dec 28, 2021
- Cytokines in the Urine of AKI patients regulate TP53 and SIRT1 and can be used as biomarkers for the early detection of AKI
Lars Erichsen, Chantelle Thimm, … James Adjaye·bioRxiv·Jan 20, 2023
- Injury induced renal fibrosis promotes cystogenesis and cyst growth in adult mice with autosomal dominant polycystic kidney disease
- Metabolomic Profiling to Identify Early Urinary Biomarkers and Metabolic Pathway Alterations in Autosomal Dominant Polycystic Kidney Disease
A. K. Hahn, E. A. Houske, … D. P. Wallace·American Journal of Physiology-Renal PhysiologyPeer-reviewed·Jun 1, 2023